|
|
Post by Thundersnow on Sept 1, 2021 12:32:55 GMT -5
Wondering if others have pondered the possibility there's more riding on this anticipated upcoming FDA approval for UTHR than meets the eye? Martine put up $105 million to expedite this approval to stay well ahead of potential competition. A second indication for the drug’s use was also submitted and approved which means the potential for success is quite large. Additionally, I believe there's another unnamed molecule and indication being investigated by these two companies. Based on this and the fact UTHR has the resources and Mannkind could still use a powerhouse partner, it would not be surprising if there's some form of buy-in, merger or something sitting in the background between UTHR and MNKD dependent on this upcoming approval. UTHR could even simply buyout specific indications which would give them total control and provide Mannkind with needed funds to pursue the many other pipeline applications desired creating a win/win for both companies. Just thinking FDA approval would be required before any such deal would transpire. If so, it would not be surprising to hear such an announcement shortly after the FDA approval. Just thinking out loud that the possibility exists and would certainly be a joy to see...well, unless you're short  Actually, I may be the only long on the board who would not be pleased with a buyout scenario. I've been in this non-productive investment for 12 years, and a buyout by anyone at this juncture would likely NOT be anywhere near what I expect to recoup for my time and money. The share price would need to be well North of $25 per share before I'd be happy. Even at $25 that is a 5x multiple of where it stands now, not considering the reverse split. Not going to happen. Otherwise, a one time payment to buy out the rights to the molecule is not particularly appealing to me either. What would be appropriate? Even if Mannkind got a payment that erased their debt and had 500 million in the bank (also unlikely), the street probably won't change its negative sentiment and send the share price to the moon. The sentiment will change when MNKD has a dependable, regular income stream with another approved product besides Afrezza and Tyvaso DPI that produces positive earnings that are showing growth, i.e., creating balance sheet verifiable shareholder value. In short, I cannot imagine a buy out scenario of any variety that would make it worthwhile for longs who have endured this investment for a decade or longer. FWIW, I doubt that Al Mann would be in favor of it, either. GLTAL Chris C A BUYOUT or Selling of a molecule is the farthest thing from Mike's head. Mike is building a Global Pharmaceutical TECHNOLOGY Company. He has big plans for their platform. UTHR is very comfortable giving MNKD a Low DD Royalty if it will make them Billions. Remember UTHR will be making BILLIONS and MNKD will be making Millions. That's a HUGE DIFFERENCE plus owning MNKD is not in UT's CORE Business Strategy. And regarding other targets?? The TS Platform is too new and no one will make a huge offer for it. Now if MNKD can convert 5 or 6 TS drugs then there's something to talk about but by then the stock price will be north of $50 which will put MNKD in the $25 Billion range. That's more likely the scenario. Also that will take 5-6 years to complete. MNKD will be in the driver seat after Oct. 15th and Mike needs to keep his foot on the pedal. Like he said..His R&D Dept is full to the gills in research. That's exactly what we want to hear. |
|
|
|
Post by Chris-C on Sept 1, 2021 13:03:02 GMT -5
Actually, I may be the only long on the board who would not be pleased with a buyout scenario. I've been in this non-productive investment for 12 years, and a buyout by anyone at this juncture would likely NOT be anywhere near what I expect to recoup for my time and money. The share price would need to be well North of $25 per share before I'd be happy. Even at $25 that is a 5x multiple of where it stands now, not considering the reverse split. Not going to happen. Otherwise, a one time payment to buy out the rights to the molecule is not particularly appealing to me either. What would be appropriate? Even if Mannkind got a payment that erased their debt and had 500 million in the bank (also unlikely), the street probably won't change its negative sentiment and send the share price to the moon. The sentiment will change when MNKD has a dependable, regular income stream with another approved product besides Afrezza and Tyvaso DPI that produces positive earnings that are showing growth, i.e., creating balance sheet verifiable shareholder value. In short, I cannot imagine a buy out scenario of any variety that would make it worthwhile for longs who have endured this investment for a decade or longer. FWIW, I doubt that Al Mann would be in favor of it, either. GLTAL Chris C A BUYOUT or Selling of a molecule is the farthest thing from Mike's head. Mike is building a Global Pharmaceutical TECHNOLOGY Company. He has big plans for their platform. UTHR is very comfortable giving MNKD a Low DD Royalty if it will make them Billions. Remember UTHR will be making BILLIONS and MNKD will be making Millions. That's a HUGE DIFFERENCE plus owning MNKD is not in UT's CORE Business Strategy. And regarding other targets?? The TS Platform is too new and no one will make a huge offer for it. Now if MNKD can convert 5 or 6 TS drugs then there's something to talk about but by then the stock price will be north of $50 which will put MNKD in the $25 Billion range. That's more likely the scenario. Also that will take 5-6 years to complete. MNKD will be in the driver seat after Oct. 15th and Mike needs to keep his foot on the pedal. Like he said..His R&D Dept is full to the gills in research. That's exactly what we want to hear. Well said! Could not agree more!!! |
|
|
|
Post by mytakeonit on Sept 1, 2021 13:03:27 GMT -5
You people wake up too early ... and it seems you all drink a lot more wine than I do. The MNKD and UTHR partnership will allow MNKD to grow a lot bigger and stronger. If so, MNKD will be worth a lot more in the future than if we are bought out now. I'm waiting for at least a valuation of $200 pps . And when we get to $150 pps ... then I will want $300 pps.  Greed ... Greed ... Greed But, that's mytakeonit |
|
|
|
Post by nylefty on Sept 1, 2021 13:05:41 GMT -5
When you're replying to a long post that quoted another long post please don't quote all that verbiage. It takes too long to scroll through all of it, especially on a phone. If you feel you have to quote something another poster has said, please edit it down to reasonable size. Thank you.
|
|
|
|
Post by mytakeonit on Sept 1, 2021 13:09:43 GMT -5
Or, you can buy a laptop phone ... hello ... can you hear me now?
But, that's mytakeonit
|
|
|
|
Post by boca1girl on Sept 1, 2021 13:23:43 GMT -5
An all cash buyout would disadvantage those who hold MNKD covered calls since their shares would most likely be called away, negating much of their gains from the larger increase in stock price. But that’s the risk you take writing covered calls. That’s why I never had the courage to do so after all these years. I’ve always thought a buyout or big pop in share price was just around the corner. Hindsight is wonderful. If you’ve been successfully writing covered calls for years, you’ve done well. If you believe that there will a sharp increase in price you can buy your calls back. I don’t believe a buyout is in our near future, and I would not like to see one anytime soon. After the PEDS trial and Afrezza sales pick up, I wouldn’t mind if we find a partner(s) for all the pipeline drugs, and become an R&D/manufacturing company and collect royalties. If there is a buyout, I hope we get a choice of cash or shares of the acquirer to avoid a huge capital gains hit. 😎 |
|
|
|
Post by BD on Sept 1, 2021 13:51:40 GMT -5
I don't want a buyout either.
I had just begun to do real well with my LVGO and it got fricken' merged into TDOC which has then proceeeded to be a total dog.
Let MNKD run.
|
|
|
|
Post by parrerob on Sept 1, 2021 14:06:01 GMT -5
My dream is not a buyout.... my dream changed recently from seeing a pps North of 30$ and selling my shares to seeing a big company in the making in order to receive in 4/6 years a lot of earnings keeping the capital intact and growing (the best investment one could think about). So no. I am not for a buyout.
In the meantime I try to keep myself flying down conscious that there are still a lot of risks in the investment and the road is long and difficult including the fact the the first product is still not sustainable in the market and the second is not approved yet.
Said that Afrezza earnings slowly improve (and from Afrezza we can have much more good surprises in the next long future as it is a golden drug 100% in our hands) and pipeline improving as well.
Ciao ciao
|
|
|
|
Post by mnkdfann on Sept 1, 2021 14:45:07 GMT -5
According to Wikipedia, UTHR has a workforce of 950 people and Mannkind's is well over 200.
I'm no great management expert, but why would UTHR want to take on so much? Most of it would be dead wood so far as UTHR's needs go.
My understanding is that lots of big Pharma companies depend on other suppliers to manufacture what they need.
UTHR indeed HAS bought out companies, but I think far more often it just licenses or partners to get what it needs.
|
|
|
|
Post by akemp3000 on Sept 1, 2021 17:01:36 GMT -5
I agree with most in that I'm not in favor of a company buyout either, nor do I think one is being discussed. IMO, it always remains a remote possibility. Back to the original thread, the thought of UTHR preferring to buyout Mannkind's low dd royalties is a possibility since most drug companies want 100% going forward. As to whether selling one sector of the pipeline to UTHR is a good idea or not, it's all about the price. I also like where the company sits now and look forward to strong, steady growth but if the price allows the company to immediately fund a strong pipeline push for things we might not even know about and to shave a few years off waiting for sufficient royalty revenues to come in, it should be a consideration. I'm fine with a deal or no deal. It's nice for the company to finally be in a good position. As always, none of us knows what MC and MR might be thinking so speculation remains the fuel for discussion. GLTA
|
|
|
|
Post by sportsrancho on Sept 1, 2021 19:46:33 GMT -5
|
|
|
|
Post by longliner on Sept 1, 2021 20:04:13 GMT -5
I copied this from kevinmik on ST: With Mannkind & United both hiring CMO positions in Danbury Ct., I think is safe to say the FDA inspection is now complete and a positive review letter from the FDA was received. Next up Tyvaso DPI FDA Approval any day now. |
|
|
|
Post by nylefty on Sept 1, 2021 20:36:08 GMT -5
I wouldn't give much credence to anything kevinmik says. He's been beating the drum for a long time for splitting MannKind into two seperate companies, thereby doubling the number of executives and increasing support staff. Recently he's been predicting that this is actually going to happen.
|
|
|
|
Post by buyitonsale on Sept 1, 2021 22:59:54 GMT -5
Roses are red, Violets are blue, I am just waiting for my sell target price, How about you ?  |
|
|
|
Post by mytakeonit on Sept 2, 2021 2:29:29 GMT -5
I don't have a sell target because I am Green.
I just hope I don't laugh too hard and bust my spleen.
But, that's mytakeonit
|
|
Greed ... Greed ... Greed
